HomeMatch CenterScheduleMarketsLeaderboardMethodologyTrack RecordServicesPricingAboutContactFAQImpressumPrivacyTerms
Skip to content
Bucephus Logo
bucephus
Analytics with Intelligence
Loading match intelligence
Will the phase 3 clinical trial of NTLA-2001 (NCT04601051) for hereditary transthyretin amyloidosis meet its primary endpoint by June 30, 2027? · Bucephus Markets